OncRef

Clinical Trial: NCT03517969

M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:National Cancer Institute (NCI)
Information Provided By:National Cancer Institute (NCI)
Last Update Posted:2026-10-09

Study Overview

Brief Summary

This phase II trial studies how well berzosertib (M6620) and carboplatin with or without docetaxel works in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). M6620 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving M6620, carboplatin and docetaxel may work better in treating patients with metastatic castration-resistant prostate cancer compared to carboplatin and docetaxel alone.

Official Title

A Phase 2 Study of M6620 (VX-970, Berzosertib) in Combination With Carboplatin Compared With Docetaxel in Combination With Carboplatin in Metastatic Castration-Resistant Prostate Cancer

Conditions

Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8

Intervention / Treatment

  • Drug: Berzosertib
  • Drug: Carboplatin
  • Drug: Docetaxel
  • Other: Laboratory Biomarker Analysis

Other Study ID Numbers

  • NCI-2018-00790
  • NCI-2018-00790
  • 10191
  • 10191
  • UM1CA186709

Start Date (Actual)

2019-05-29

Primary Completion Date (Actual)

2021-08-10

Study Completion Date (Estimated)

2027-04-03

Enrollment (Actual)

73

Study Type

Interventional

Phase

Phase 2